NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007 (Nine months ended March 31, 2007)
Business Overview: NAI operates in two primary segments: Private Label Contract Manufacturing (providing manufacturing services for nutritional supplements) and Branded Products (marketing and distributing its own and third-party branded products, including the "Pathway to Healing" line and the "As We Change" catalog). The company recently acquired Real Health Laboratories, Inc. (RHL) in December 2005 to expand its branded product portfolio.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 12% year-over-year for the nine-month period, driven by an 8% increase in private label contract manufacturing and a 32% increase in branded products.
• Profitability Decline: Despite revenue growth, operating income decreased 10% and net income decreased 12% compared to the prior year. This was primarily due to increased selling, general, and administrative (SG&A) expenses ($3.2 million increase) related to the RHL acquisition and investments in the "As We Change" catalog.
• Margin Improvement: Gross profit margin improved to 22.8% from 21.0% due to a favorable shift in sales mix toward higher-margin branded products.
• Customer Concentration: Dependence on top customers decreased slightly; the two largest private label customers accounted for 71% of total net sales in the nine-month period, down from 76% in the prior year.
• Debt Reduction: Total consolidated debt decreased significantly to $5.1 million from $15.9 million at the end of the prior fiscal year, largely due to the repayment of the working capital line of credit.

Guidance, Outlook, and Risks

• Outlook: Management anticipates revenue and profitability for fiscal 2007 will be lower than fiscal 2006. The fourth quarter of fiscal 2006 was a record quarter due to initial shipments to a new customer, a level not expected to be repeated.
• Dr. Cherry Product Line: Dr. Cherry ceased airing his weekly television program in April 2007, which was the primary customer acquisition vehicle for the "Pathway to Healing" product line. Sales for this line decreased 16% in the nine-month period. Management is evaluating alternative marketing plans to sustain the line but acknowledges a near-term negative impact on new customer acquisition.
• Goodwill Impairment Risk: The company holds approximately $7.5 million in goodwill associated with the branded products unit. If the "Pathway to Healing" line cannot be sustained or is discontinued, a material goodwill impairment charge may be required.
• Inventory Risk: Approximately $3.0 million of inventory is related to a purchase order with rescheduled delivery dates. Management currently believes a write-down is remote but notes that changes in customer demand could materially impact inventory value.
• Liquidity: The company has $3.8 million in cash and $6.4 million available under its line of credit. Management believes these resources are sufficient to fund operations for the next 12 months.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the top two private label customers, which collectively represent over 70% of total revenue.
• Dr. Cherry Transition: Monitor the success of new marketing strategies for the "Pathway to Healing" line following the cessation of the TV program and watch for potential goodwill impairment charges.
• Inventory Valuation: Confirm the status of the $3.0 million inventory tied to the rescheduled purchase order and assess the risk of obsolescence.
• Debt Covenants: Review the amended credit facility terms, specifically the total liabilities to tangible net worth covenant (1.25/1.0) and fixed charge coverage ratio.
• Foreign Exchange Exposure: Assess the impact of currency fluctuations (Euro and Swiss Franc) on the European subsidiary (NAIE), which accounts for a significant portion of non-U.S. sales.